Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
Hodgkin lymphoma (HL) is a rare malignancy accounting for roughly 15% of all lymphomas and mostly affecting young patients. A second peak is seen in patients above 60 years of age. The history of HL treatment represents a remarkable success story in which HL has turned from an incurable disease to a...
Main Authors: | Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, Andreas Engert, Stephanie Sasse |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/5/1125 |
Similar Items
-
Nodular lymphocyte-predominant Hodgkin’s lymphoma: Principles of diagnosis and treatment
by: T N Moiseeva, et al.
Published: (2015-11-01) -
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
by: YuanBo Xue, et al.
Published: (2021-02-01) -
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
by: Lydia Visser, et al.
Published: (2016-12-01) -
Coexistence Between Hodgkin’s Lymphoma and Renal Cell Cancer: Case Report
by: Mustafa Karabıçak, et al.
Published: (2014-11-01) -
Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up
by: Novella Pugliese, et al.
Published: (2021-04-01)